NEWS IN BRIEF Neratinib Graduates to I-SPY 3

publicité

publicité

Documents connexes

patritumab selected for I-SPY 2 TRIAL in breast cancer.docx

patritumab selected for I-SPY 2 TRIAL in breast cancer.docx

I-SPY 2 — Toward More Rapid Progress in Breast Cancer Treatment

I-SPY 2 — Toward More Rapid Progress in Breast Cancer Treatment

I-SPY 2 Shows Efficacy of T-DM1-Pertuzumab.docx

I-SPY 2 Shows Efficacy of T-DM1-Pertuzumab.docx

Open access

The Marseille SIRIC, which IPC is part of together with AP

The Marseille SIRIC, which IPC is part of together with AP

A STUDY OF PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH

A STUDY OF PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH

Symposium Satellite HER2+ Early Breast Cancer Therapy:

Symposium Satellite HER2+ Early Breast Cancer Therapy:

therapy-specific side effects of aromatase inhibi-

therapy-specific side effects of aromatase inhibi-

translational medicine

translational medicine

new england journal medicine

new england journal medicine

ETUDES (CLINIQUE DU SEIN)

ETUDES (CLINIQUE DU SEIN)

Fight Breast Cancer with Exercise bOOK reVieW/ critique De liVre S UE

Fight Breast Cancer with Exercise bOOK reVieW/ critique De liVre S UE